

Can taking a zinc supplement during pregnancy reduce the symptoms of depression both before and after the baby is born?

Submission date 12/06/2018	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
Registration date 18/07/2018	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 17/07/2018	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Perinatal depression is a depressive illness that affects women in pregnancy around childbirth or within the first year following birth. It is experienced as persistent low mood and it is estimated to affect 10-15% of women in the UK. The cost to health and social services is estimated at £1.8 billion for each one-year cohort of births in the UK and it is one of the leading causes of deaths amongst new mothers. Besides being difficult for affected women, perinatal depression can have negative effects on the growth and development of their babies and affect the well-being of the entire family. Research shows a clear relationship between zinc deficiency and the development of mood disorders. Evidence also suggests that zinc supplementation helps to reduce the symptoms of depression in both animals and humans. It is recognised that women who are pregnant and breastfeeding are at risk of lower levels of zinc because of the high demand from the developing and feeding baby. Studies in the perinatal period are however limited, highlighting the need to carry out a study to determine whether the same anti-depressant effects are seen in this group of women. To make the future study as successful as possible the aim of this study is to first test the practicality of the study design.

Who can participate?

Pregnant women

What does the study involve?

At assessment participants are classified as either having a history of depression or onset of depression in pregnancy and as either users or non-users of antidepressants. The women not taking an antidepressant are randomly allocated to take either a placebo (dummy supplement) or zinc. The women taking an antidepressant are also randomly allocated to take either antidepressant and zinc or antidepressant and placebo. On a daily basis for the duration of their pregnancy and for 4 weeks after giving birth, participants take either a placebo or a zinc tablet on its own or with an antidepressant depending on which group they are assigned to. At five different time points they have a blood test to measure their zinc levels, and complete a food diary and questionnaires that evaluate the amount of zinc consumed from their diet and their mood. Adherence is measured by counting pills. Participants are also provided with a diary so

they can record the date and time the tablet is taken, side effects experienced and any missed days. The researcher contacts the participants by telephone on a fortnightly basis to discuss any side effects or issues with adherence. Likewise, the participants have both telephone and email access to the researcher and their midwife should they have any concerns about their supplement use. The diaries are also collected at the scheduled appointments.

What are the possible benefits and risks of participating?

The potential benefits to the study participants include: closer supervision and monitoring of their mental health; an awareness of their dietary intake; a reduction of depressive symptoms; and new knowledge. There is an awareness of potential drug-zinc interactions and these will be identified through regular assessment and managed on a case by case basis in collaboration with the clinical team. Too much zinc may be harmful, symptoms include: nausea, vomiting, loss of appetite, stomach cramps, diarrhoea and headaches. When people take too much zinc for a long time, they sometimes have problems such as low copper levels, lower immunity, and low levels of HDL cholesterol (the "good" cholesterol). Thus, women's individual overall supplement intake will also be assessed to ensure that it does not exceed the safe upper limit of 40 mg per day.

Where is the study run from?

Ashford and St Peter's Hospitals NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

June 2018 to July 2019

Who is funding the study?

University of Surrey (UK)

Who is the main contact?

Mrs Nadine Page

n.page@surrey.ac.uk

Contact information

Type(s)

Scientific

Contact name

Mrs Nadine Page

Contact details

University of Surrey

School of Health Sciences

Guildford

United Kingdom

GU2 7LS

+44 (0)7930 728074

n.page@surrey.ac.uk

Additional identifiers

Protocol serial number

Study information

Scientific Title

Can taking a zinc supplement during pregnancy reduce the symptoms of perinatal depression?

Acronym

ZnPND

Study objectives

Zinc supplementation either together with or without antidepressant drugs improves the symptoms of depression in pregnancy and the postnatal period.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Single-centre randomised controlled trial

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Perinatal depression

Interventions

At assessment women will be classified as either having a history of depression or onset of depression in pregnancy. Antidepressant use is found to be a prognostic variable. Hence, at the recruitment women will be classified as either users or non-users of antidepressants and subdivided into two groups:

- Women not taking antidepressants
- Women taking antidepressants

To control for the effect of antidepressant use which is a confounder a stratified randomisation will be used so that the randomisation scheme is performed separately for antidepressant users and for non-users. The treatment (zinc) and the control (placebo) will be randomised to participants within each stratum.

The women not taking an antidepressant will be randomly allocated into one of two arms and given either:

- Placebo alone
- Zinc alone

The women taking an antidepressant will also be randomly allocated into one of two arms and given either:

- Antidepressant and zinc
- Antidepressant and placebo

To avoid the potential sources of bias, double blindness or masking will be adopted in allocating treatments. Neither the participants nor the researchers will know which participant belong to which group. Randomisation codes will be generated by the web based application called sealed envelope available at <https://www.sealedenvelope.com/>.

On a daily basis for the duration of their pregnancy and for 4 weeks post giving birth, women will be required to take either a placebo or a single 10mg zinc tablet, on its own or adjunct to an antidepressant depending on which group they are assigned to (see above).

At five different time points they will also be required to have a blood test to measure their zinc levels, complete a food diary and questionnaires that evaluate both the amount of zinc consumed from diet and mood.

Adherence will be measured by pill counts, the standard for monitoring patient adherence for both experimental and clinical drugs (Lee et al. 2007). Upon starting the study each woman will receive a supply of either zinc supplements or placebo and unbeknown to her more tablets will be supplied than needed. At the scheduled study appointments women will be asked to return any excess supplements. Pill counts will be calculated by the PhD researcher as the number of pills taken (the number of pills dispensed minus the number of pills counted) to confirm adherence. The number of pills expected to have been taken will be calculated by multiplying the daily dose by the number of days since the date dispensed. The supply will then be replenished accordingly until the next appointment and so forth until the end of the study. The women will also be provided with a diary so they can record the date, time the tablet is taken, side effects experienced and any missed days. The PhD researcher will contact the women by telephone on a fortnightly basis to discuss any adverse reactions and/or issues with adherence. Likewise, the women will have both telephone and email access to the PhD researcher and their midwife in between time should they have any concerns about their supplement use. The diaries will also be collected at the scheduled appointments.

Intervention Type

Supplement

Primary outcome(s)

Severity of depressive symptoms, measured using the Edinburgh Post Natal Depression Score at 6-12 weeks baseline, 20 weeks/anomaly scan, 28-30 weeks, birth visit up to 10 days post delivery, and 4 weeks post delivery

Key secondary outcome(s)

Measured at 6-12 weeks baseline, 20 weeks/anomaly scan, 28-30 weeks, birth visit up to 10 days post delivery, and 4 weeks post delivery:

1. Zinc levels in the blood, measured using a blood test
2. Zinc intake from diet, measured using the Zinc Food Frequency Questionnaire and 4-day food and drink diary

Completion date

31/07/2019

Eligibility

Key inclusion criteria

1. Pregnant women irrespective of age, ethnicity, socioeconomic status, pregnancy status (primigravida or multigravida)
2. Pregnant women may be prescribed an antidepressant or not
3. Pregnant women may be taking supplements or not

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

Women infected with HIV will be excluded. Whilst they are particularly susceptible to zinc deficiency, the HIV virus also requires zinc and excessive dietary zinc has been linked with declining CD4 cell counts and reduced survival. Baum et al. (2010) carried out a RCT of zinc supplementation to prevent immunological failure in HIV-infected adults and whilst no serious side effects were reported, the dose was significantly lower than the suggested therapeutic dose for this study. More research is needed; hence women who are HIV positive will be excluded.

Date of first enrolment

20/08/2018

Date of final enrolment

19/07/2019

Locations

Countries of recruitment

United Kingdom

Study participating centre

Ashford and St Peter's Hospitals NHS Foundation Trust

Peter's Hospital

Chertsey

United Kingdom

KT16 OPZ

Sponsor information

Organisation

University of Surrey

ROR

<https://ror.org/00ks66431>

Funder(s)

Funder type

University/education

Funder Name

University of Surrey

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

Universities (academic only)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date